248 related articles for article (PubMed ID: 38267569)
1. Antibodies from dengue patients with prior exposure to Japanese encephalitis virus are broadly neutralizing against Zika virus.
Salem GM; Galula JU; Wu SR; Liu JH; Chen YH; Wang WH; Wang SF; Song CS; Chen FC; Abarientos AB; Chen GW; Wang CI; Chao DY
Commun Biol; 2024 Jan; 7(1):15. PubMed ID: 38267569
[TBL] [Abstract][Full Text] [Related]
2. T Cell Responses Induced by Attenuated Flavivirus Vaccination Are Specific and Show Limited Cross-Reactivity with Other Flavivirus Species.
Grifoni A; Voic H; Dhanda SK; Kidd CK; Brien JD; Buus S; Stryhn A; Durbin AP; Whitehead S; Diehl SA; De Silva AD; Balmaseda A; Harris E; Weiskopf D; Sette A
J Virol; 2020 May; 94(10):. PubMed ID: 32132233
[TBL] [Abstract][Full Text] [Related]
3. Priming with Japanese encephalitis virus or yellow fever virus vaccination led to the recognition of multiple flaviviruses without boosting antibody responses induced by an inactivated Zika virus vaccine.
Li Y; Merbah M; Wollen-Roberts S; Beckman B; Mdluli T; Curtis DJ; Currier JR; Mendez-Rivera L; Dussupt V; Krebs SJ; De La Barrera R; Michael NL; Paquin-Proulx D; Eller MA; Koren MA; Modjarrad K; Rolland M
EBioMedicine; 2023 Nov; 97():104815. PubMed ID: 37793212
[TBL] [Abstract][Full Text] [Related]
4. Dengue Virus Envelope Dimer Epitope Monoclonal Antibodies Isolated from Dengue Patients Are Protective against Zika Virus.
Swanstrom JA; Plante JA; Plante KS; Young EF; McGowan E; Gallichotte EN; Widman DG; Heise MT; de Silva AM; Baric RS
mBio; 2016 Jul; 7(4):. PubMed ID: 27435464
[TBL] [Abstract][Full Text] [Related]
5. Cross-Reactive T Cell Immunity to Dengue and Zika Viruses: New Insights Into Vaccine Development.
Elong Ngono A; Shresta S
Front Immunol; 2019; 10():1316. PubMed ID: 31244855
[TBL] [Abstract][Full Text] [Related]
6. Seroprevalence of dengue, Japanese encephalitis and Zika among long-term expatriates in Thailand.
Kitro A; Imad HA; Pisutsan P; Matsee W; Sirikul W; Sapbamrer R; Rapheal E; Fernandez S; Cotrone TS; Farmer AR; Hunsawong T; Silachamroon U; Chatapat L; Olanwijitwong J; Salee P; Anderson KB; Piyaphanee W
J Travel Med; 2024 Mar; 31(2):. PubMed ID: 38335250
[TBL] [Abstract][Full Text] [Related]
7. Seroprevalence of Flavivirus Neutralizing Antibodies in Thailand by High-Throughput Neutralization Assay: Endemic Circulation of Zika Virus before 2012.
Yamanaka A; Matsuda M; Okabayashi T; Pitaksajjakul P; Ramasoota P; Saito K; Fukasawa M; Hanada K; Matsuura T; Muramatsu M; Shioda T; Suzuki R
mSphere; 2021 Aug; 6(4):e0033921. PubMed ID: 34259560
[TBL] [Abstract][Full Text] [Related]
8. Analysis of cross-reactivity among flaviviruses using sera of patients with dengue showed the importance of neutralization tests with paired serum samples for the correct interpretations of serological test results for dengue.
Maeki T; Tajima S; Ando N; Wakimoto Y; Hayakawa K; Kutsuna S; Kato F; Taniguchi S; Nakayama E; Lim CK; Saijo M
J Infect Chemother; 2023 May; 29(5):469-474. PubMed ID: 36702208
[TBL] [Abstract][Full Text] [Related]
9. Effect of previous heterologous flavivirus vaccinations on human antibody responses in tick-borne encephalitis and dengue virus infections.
Roßbacher L; Malafa S; Huber K; Thaler M; Aberle SW; Aberle JH; Heinz FX; Stiasny K
J Med Virol; 2023 Nov; 95(11):e29245. PubMed ID: 38009693
[TBL] [Abstract][Full Text] [Related]
10. Defining the impact of flavivirus envelope protein glycosylation site mutations on sensitivity to broadly neutralizing antibodies.
Contreras M; Stuart JB; Levoir LM; Belmont L; Goo L
mBio; 2024 Feb; 15(2):e0304823. PubMed ID: 38193697
[TBL] [Abstract][Full Text] [Related]
11. Identification of Anti-Premembrane Antibody as a Serocomplex-Specific Marker To Discriminate Zika, Dengue, and West Nile Virus Infections.
Hsieh SC; Tsai WY; Tsai JJ; Stone M; Simmons G; Busch MP; Lanteri M; Stramer SL; Balmaseda A; Harris E; Wang WK
J Virol; 2021 Sep; 95(19):e0061921. PubMed ID: 34232731
[TBL] [Abstract][Full Text] [Related]
12. Potent Zika and dengue cross-neutralizing antibodies induced by Zika vaccination in a dengue-experienced donor.
Dussupt V; Sankhala RS; Gromowski GD; Donofrio G; De La Barrera RA; Larocca RA; Zaky W; Mendez-Rivera L; Choe M; Davidson E; McCracken MK; Brien JD; Abbink P; Bai H; Bryan AL; Bias CH; Berry IM; Botero N; Cook T; Doria-Rose NA; Escuer AGI; Frimpong JA; Geretz A; Hernandez M; Hollidge BS; Jian N; Kabra K; Leggat DJ; Liu J; Pinto AK; Rutvisuttinunt W; Setliff I; Tran U; Townsley S; Doranz BJ; Rolland M; McDermott AB; Georgiev IS; Thomas R; Robb ML; Eckels KH; Barranco E; Koren M; Smith DR; Jarman RG; George SL; Stephenson KE; Barouch DH; Modjarrad K; Michael NL; Joyce MG; Krebs SJ
Nat Med; 2020 Feb; 26(2):228-235. PubMed ID: 32015557
[TBL] [Abstract][Full Text] [Related]
13. Japanese Encephalitis Virus Vaccination Elicits Cross-Reactive HLA-Class I-Restricted CD8 T Cell Response Against Zika Virus Infection.
Tarbe M; Dong W; Hu G; Xu Y; Sun J; Grayo S; Chen X; Qin C; Zhao J; Liu L; Li X; Leng Q
Front Immunol; 2020; 11():577546. PubMed ID: 33101303
[TBL] [Abstract][Full Text] [Related]
14. Serological evidence of DENV, JEV, and ZIKV among the indigenous people (Orang Asli) of Peninsular Malaysia.
Khor CS; Mohd-Rahim NF; Hassan H; Tan KK; Zainal N; Teoh BT; Sam SS; Khoo JJ; Lee HY; Lim YA; Abubakar S
J Med Virol; 2020 Aug; 92(8):956-962. PubMed ID: 31814135
[TBL] [Abstract][Full Text] [Related]
15. Dengue and Zika Virus Domain III-Flagellin Fusion and Glycan-Masking E Antigen for Prime-Boost Immunization.
Lin HH; Yang SP; Tsai MJ; Lin GC; Wu HC; Wu SC
Theranostics; 2019; 9(16):4811-4826. PubMed ID: 31367259
[TBL] [Abstract][Full Text] [Related]
16. Cross-reactive dengue virus-derived monoclonal antibodies to Zika virus envelope protein: Panacea or Pandora's box?
Gunawardana SA; Shaw RH
BMC Infect Dis; 2018 Dec; 18(1):641. PubMed ID: 30526531
[TBL] [Abstract][Full Text] [Related]
17. The immunogenicity of tetravalent dengue DNA vaccine in mice pre-exposed to Japanese encephalitis or Dengue virus antigens.
Prompetchara E; Ketloy C; Keelapang P; Sittisombut N; Ruxrungtham K
Asian Pac J Allergy Immunol; 2015 Sep; 33(3):182-8. PubMed ID: 26342114
[TBL] [Abstract][Full Text] [Related]
18. Human antibody response to Zika targets type-specific quaternary structure epitopes.
Collins MH; Tu HA; Gimblet-Ochieng C; Liou GA; Jadi RS; Metz SW; Thomas A; McElvany BD; Davidson E; Doranz BJ; Reyes Y; Bowman NM; Becker-Dreps S; Bucardo F; Lazear HM; Diehl SA; de Silva AM
JCI Insight; 2019 Apr; 4(8):. PubMed ID: 30996133
[TBL] [Abstract][Full Text] [Related]
19. Longitudinal Analysis of Antibody Cross-neutralization Following Zika Virus and Dengue Virus Infection in Asia and the Americas.
Montoya M; Collins M; Dejnirattisai W; Katzelnick LC; Puerta-Guardo H; Jadi R; Schildhauer S; Supasa P; Vasanawathana S; Malasit P; Mongkolsapaya J; de Silva AD; Tissera H; Balmaseda A; Screaton G; de Silva AM; Harris E
J Infect Dis; 2018 Jul; 218(4):536-545. PubMed ID: 29618091
[TBL] [Abstract][Full Text] [Related]
20. Analysis of cross-reactivity between flaviviruses with sera of patients with Japanese encephalitis showed the importance of neutralization tests for the diagnosis of Japanese encephalitis.
Maeki T; Tajima S; Ikeda M; Kato F; Taniguchi S; Nakayama E; Takasaki T; Lim CK; Saijo M
J Infect Chemother; 2019 Oct; 25(10):786-790. PubMed ID: 31105002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
